Policies and research funding

Orphan drugs: Understanding the rare disease market and its dynamics

Volumn , Issue , 2013, Pages 145-186

  Wilson, Chris ^a  

^a NONE

Author keywords

EUROPLAN; Framework Programmes; IRDiRC; National Plans; Policies; TRND

Indexed keywords

EID: 84904142550     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1533/9781908818393.145     Document Type: Chapter

References (3)

1. Aymé S., Hivert V. Orphanet-RDPlatform Report: Report on rare disease research, its determinants in Europe and the way forward 2011, Available from:, [Accessed 01 April 2012]. http://www.asso.orpha.net/RDPlatform/upload/file/RDPlatform_final_report.pdf.
2. Clinical Added Value for Orphan Drugs (CAVOD) Creation of a process for the exchange of knowledge between Member States and European authorities on the scientific assessment of the clinical added value for orphan medicines (Final study report) 2011, EAHC/2010/Health/05. Available from:, [Accessed 01 April 2012]. http://www.ec.europa.eu/eahc/documents/news/CAVOD_Final%20Report_vf_corrected_281011.pdf.
3. Villarreal M.A. CRS Report for Congress: Library of Congress (US) 2001. Orphan Drug Act: Background and Proposed Legislation in the 107th Congress 2001, 1-6. Order Code RS2097.